Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$68.04 USD

68.04
1,959,674

-0.08 (-0.12%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $68.04 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Can Exact Sciences (EXAS) Keep the Earnings Streak Alive This Quarter?

Exact Sciences (EXAS) can be a harbinger of out performance and a signal for a strong earnings profile on the back of its favorable Zacks rank and earnings ESP in the positive territory.

    Surging Earnings Estimates Signal Good News for Exact Sciences Corporation (EXAS)

    Exact Sciences Corporation (EXAS) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.

      Exact Sciences Corporation (EXAS) Jumps: Stock Rises 6.2%

      Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise nearly 6% on the day after the company delivered yet another quarter of greater than 100% top-line growth.

        Is a Beat in the Cards for ImmunoGen (IMGN) in Q2 Earnings?

        ImmunoGen has made significant progress with its ovarian cancer pipeline candidate. Let's see if the company can come up with a beat this earnings season.

          Why Exact Sciences (EXAS) Might Surprise This Earnings Season

          Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

            Tirthankar Chakraborty headshot

            New Strong Buy Stocks for July 19th

            Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

              Tirthankar Chakraborty headshot

              New Strong Buy Stocks for July 17th

              Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

                Why Exact Sciences (EXAS) Could Beat Earnings Estimates Again

                Exact Sciences (EXAS) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.

                  Exact Sciences (EXAS) Shows Strength: Stock Gains 11.7%

                  Exact Sciences Corp. (EXAS) shares jumped almost 12% in the last trading session.

                    Pfizer's Leukemia Candidate Gets Priority Review in U.S.

                    Pfizer Inc. (PFE) announced that its Biologics License Application (BLA) for leukemia candidate inotuzumab ozogamicin has been accepted for priority review by the FDA.

                      Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?

                      Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.

                        Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?

                        Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.

                          Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS

                          Here we have three pharma companies that are set to report fourth-quarter results on Feb 21. Let's see how things are shaping up for this quarter.

                            Merrimack (MACK): What Awaits the Stock in Q4 Earnings?

                            Merrimack Pharmaceuticals, Inc. (MACK) is scheduled to report fourth-quarter 2016 results in the next week. Last quarter, Merrimack delivered a positive earnings surprise of 23.33%.

                              Geron (GERN) Q4 Earnings: What's in Store for the Stock?

                              Geron Corporation (GERN) is expected to report fourth-quarter 2016 results next week. In the last reported quarter, the company recorded a positive earnings surprise of 66.67%.

                                Can Fitbit (FIT) Stock Surprise Investors Post Q4 Earnings?

                                Fitbit Inc. (FIT) is set to report fourth-quarter 2016 results on Feb 22. Last quarter, the company posted a positive earnings surprise of 18.18%.

                                  BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?

                                  We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports fourth-quarter and full-year 2016 results on Feb 23

                                    Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y

                                    Alexion Pharmaceuticals, Inc.'s (ALXN) fourth-quarter 2016 earnings (including stock-based compensation expense) of $1.10 cents per share compared with the year ago earnings of 78 cents.

                                      Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat

                                      Alkermes plc (ALKS) reported loss of 4 cents per share (including the impact of share-based compensation expense) in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 19 cents.

                                        Ligand (LGND) Q4 Earnings: Will the Stock Pull a Surprise?

                                        Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report fourth-quarter 2016 results on Feb 23, after the market closes.

                                          What's in Store for ImmunoGen (IMGN) this Earnings Season?

                                          ImmunoGen, Inc. (IMGN) is scheduled to report results for the three months ended Dec 31, 2016 on Feb 17, before the opening bell. Overall, the company has posted an average negative surprise of 19.34%.

                                            The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals

                                            The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals

                                              Swarup Gupta headshot

                                              5 Great Biotech Stocks to Buy Now

                                              Biotechs have stabilized and still offer the potential to deliver substantial returns.

                                                Cara Therapeutics (CARA) Worth Watching: Stock Jumps 8%

                                                Cara Therapeutics, Inc. (CARA) was a big mover last session, as the company saw its shares climb over 8% on the day.

                                                  Pfizer (PFE) C. Difficile Vaccine Positive in Phase II Study

                                                  Pfizer Inc. (PFE) announced positive top-line results from a phase II study on its investigational vaccine candidate, PF-06425090, for the prevention of clostridium difficile infection.